Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.
Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.
Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.
Attaya Suvannasankha, MD, discusses future research directions with bispecific antibodies in patients with multiple myeloma and potential methods for mitigating adverse effects in this population.
REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.
Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.
The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma.